Prime Medicine (PRME) Liabilities and Shareholders Equity (2021 - 2026)

Prime Medicine (PRME) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $294.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 10.19% year-over-year to $294.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 6.84% YoY), and the FY2025 full-year result was $342.7 million, up 15.2% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $294.7 million, down from $342.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $385.0 million in Q3 2025 and bottomed at $193.9 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $297.5 million (2024), against an average of $295.8 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity sank 46.2%; it then jumped 53.47% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $360.3 million in 2022, then plunged by 46.2% to $193.9 million in 2023, then soared by 53.47% to $297.5 million in 2024, then advanced by 15.2% to $342.7 million in 2025, then dropped by 14.01% to $294.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $294.7 million (Q1 2026), $342.7 million (Q4 2025), and $385.0 million (Q3 2025), per Business Quant data.

Peer Comparison